Colorado Senate passes bill to regulate compounded weight loss drugs
perigon
Last updated: April 18, 2026
The state Senate has approved a bill aimed at regulating the production of copycat versions of popular weight loss drugs, specifically those in the GLP-1 class. This legislation seeks to address concerns surrounding compounded versions of widely recognized medications like Ozempic and Wegovy.
- The bill mandates that compounding pharmacies creating these GLP-1 drugs must adhere to specific regulatory standards. It requires them to register with the state and disclose the source of their active pharmaceutical ingredients.
- Furthermore, the legislation compels these pharmacies to provide clear labeling for their compounded drugs, indicating that they are not FDA-approved and are made from different ingredients than the brand-name counterparts.
- A crucial aspect of the bill is the requirement for compounding pharmacies to offer warnings about potential risks associated with compounded drugs, including variations in efficacy and safety profiles compared to FDA-approved medications.
- The bill also establishes a fee structure for compounding pharmacies to help fund regulatory oversight. The intention is to enhance patient safety and transparency in the market for these increasingly sought-after weight loss treatments.
